This content is not available in your region

Takeda's $62 billion Shire bid faces Nov. 6 EU antitrust deadline

Access to the comments Comments
Takeda's $62 billion Shire bid faces Nov. 6 EU antitrust deadline
FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon   -   Copyright  Kim Kyung Hoon(Reuters)
Text size Aa Aa

BRUSSELS (Reuters) – EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical’s <4502.T> $62-billion takeover of London-listed Shire Plc <SHP.L>, the European Commission said on Friday.

The EU competition enforcer can give the green light with or without demanding concessions or open a four-month long investigation if it has serious concerns.

The deal, the largest overseas acquisition by a Japanese company, would elevate the combined company into the list of the top 10 global drugmakers. It would be a leader in gastroenterology, neuroscience, oncology, rare diseases and blood-derived therapies used for serious conditions such as haemophilia.

Authorities in the United States, China and Brazil have already given unconditional approvals for the deal.

(Reporting by Foo Yun Chee; Editing by Emelia Sithole-Matarise)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.